TelomEYE is a company working on ophthalmic treatments to prevent and improve age-related ophthalmologic disorders such as presbyopia, cataracts and macular degeneration, each of which is a significant medical need.
Presbyopia, a condition which makes it harder for the eyes to focus on close objects after early 40s’, is one of the most common age-related ophthalmologic disorders in the world, with an estimated 2.1 billion sufferers worldwide by 2030 according to the World Health Organisation. It is a fact that everyone over the age of 40s eventually faces the need for reading glasses.
TelomEYE treatment has a unique formulation that prevents the cellular aging of the compartments of the eyes and may even rejuvenate them. Starting in our late 30s, daily use of TelomEYE could remove or delay the necessity of reading glasses at later stages of life. Patients with dry eye syndrome which is a very common health problem may have beneficial effects as well.
TelomEYE is a privately held Canadian ophthalmology & biotech company founded in September 2021 by ophthalmologists Iskender Alkin Solmaz MD, Isilay Kavadarli MD and entrepreneur Kubilay Turkmen in Ontario, Canada.
TelomEYE Pharmaceuticals Corporation has completed successful $1 million USD post-seed funding round, valuing the company at $10 million USD. The round was co-led by healthcare mogul Mehmet Ali Aydınlar, Re-Pie Venture Capital Fund, and investment banker Kerim Kotan, along with other angel investors. With this financing, TelomEYE will be able to complete phase I & II human studies for their novel, patented therapy in ophthalmology. This therapy could be the start of a new era for treating many ophthalmologic age-related disorders including presbyopia, cataracts and macular degeneration.
